<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-10-26</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://deepin-community.github.io/sig-dde-porting/posts/dde-qt6.8-porting-guide/?utm_source=atom_feed">DDE Qt 6.8 é€‚é…è¯´æ˜</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/deepin-community-github-io-sig-dde-porting-posts-dde-qt6-8-porting-guide-utm-source-atom-feed/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450445/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Guidelines for the Prophylaxis and Treatment of Peritoneal Metastases From Colorectal Cancer: A GRADE-Approach for Evidence Evaluation and Recommendations</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450445-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Colorectal peritoneal metastases (CPM) are common in colorectal cancer patients. This article aims to provide GRADE guidelines for the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in two clinical situations: (1) To determine the value of adjuvant HIPEC for the prevention of CPM in high-risk colorectal cancer patients; (2) to determine the impact on survival of cytoreductive surgery and HIPEC followed by adjuvant systemic chemotherapy as compared to systemic chemotherapy alone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450725/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Specific Morphology of Coronary Artery Aneurysms in Mainly White Patients With Kawasaki Disease: Initial Data From the Cardiac Catheterization in Kawasaki Disease Registry</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450725-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: That distal CAAs were only present together with proximal ones will hopefully reduce diagnostic CCs in patients with KD without echocardiographically detected proximal CAAs. Furthermore, this study gives valuable insights into dimensional specifics of CAAs in patients with KD. As an ongoing registry, future analyses will further explore long-term outcomes and performed treatments, helping to refine clinical long-term strategies for patients with &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Microvascular inflammation in kidney allografts includes distinct phenotypes, with various disease progression and allograft outcomes. Our findings support the clinical use of additional rejection phenotypes to standardize diagnostics for kidney allografts. (Funded by OrganX. ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Microvascular inflammation in kidney allografts includes distinct phenotypes, with various disease progression and allograft outcomes. Our findings support the clinical use of additional rejection phenotypes to standardize diagnostics for kidney allografts. (Funded by OrganX. ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450797/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Development of the EULAT eCollect application for electronic data collection within the European-Latin American consortium towards eradication of preventable gallbladder cancer - EULAT Eradicate GBC</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450797-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The European-Latin American Consortium towards Eradication of Preventable Gallbladder Cancer (GBC) - EULAT Eradicate CVB is collecting high-quality data and samples in four Latin American countries with a high incidence of GBC: Argentina, Bolivia, Chile and Peru. The goal is to build a unique biorepository integrated with a customized informatics platform, identify, validate, and functionally characterize novel GBC risk biomarkers, and develop GBC prediction models integrating &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450931/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Cortisol dynamics and GR-dependent feedback regulation in zebrafish larvae exposed to repeated stress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450931-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Zebrafish larvae show a rapid increase in cortisol in response to acute stressors, followed by a decline. While these responses are documented, both the duration of the refractory period to repeated stressors and the role of glucocorticoid receptors (GR) in specific phases of the glucocorticoid negative feedback are still being clarified. We explored these questions using water vortices as stressors, combined with GR blockage and measurements of whole-body cortisol in zebrafish larvae &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451122/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Overcoming Communication Barriers in Clinical Care: A Digital Translation Platform</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451122-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The pilot study demonstrates the feasibility of the Translatly platform in real-world healthcare settings. It shows potential to improve communication and patient outcomes by addressing language barriers. Despite its potential, challenges such as translator availability highlight the need for further &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451370/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Nuclei Detection and Segmentation of Histopathological Images Using a Feature Pyramidal Network Variant of a Mask R-CNN</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451370-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cell nuclei interpretation is crucial in pathological diagnostics, especially in tumor specimens. A critical step in computational pathology is to detect and analyze individual nuclear properties using segmentation algorithms. Conventionally, a semantic segmentation network is used, where individual nuclear properties are derived after post-processing a segmentation mask. In this study, we focus on showing that an object-detection-based instance segmentation network, the Mask R-CNN, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451431/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">The Use of Social Media in Orthopedic and Trauma Surgery Education: A Cross-Sectional Survey of German-Speaking Residents and Medical Students</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451431-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Orthopedic residents and students are high-volume social media users but engage more passively with professional content. While most value educational material, concerns about privacy violations and inappropriate posts remain &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451658/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Inflammatory Signals Across the Spectrum: A Detailed Exploration of Acute Appendicitis Stages According to EAES 2015 Guidelines</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451658-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Background: In this retrospective study, we evaluate the diagnostic utility of C-reactive protein (CRP) and leucocyte count within the EAES 2015 guidelines for acute appendicitis (AA) in differentiating uncomplicated (UAA) from complicated AA (CAA). Methods: Conducted at a tertiary care center in Germany, the study included 285 patients over 18 years who were diagnosed with AA from January 2019 to December 2021. Patient data included demographics, inflammatory markers, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452517/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Validation of the Short Parallel and Extra-Short Form of the Heidelberg Figural Matrices Test (HeiQ)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452517-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Figural matrices tests are frequently used to measure fluid intelligence. The HeiQ-an operation-oriented figural matrices test-was developed to tackle limitations of previous matrices tests, mainly the possibility of excluding distractors based on superficial features instead of actively solving the items. However, allowing for a total administration time of 60 min for the assessment of one construct is not feasible in many study designs. Thus, the goal of this study was to develop three &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452571/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452571-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Many pwCF under ETI therapy have Cmax values for elexacaftor and ivacaftor above the recommended range, even on reduced doses or before the tmax was reached. This highlights the value of a TDM program. Further pharmacokinetic studies are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452767/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Association of Antibody Responses to &lt;em&gt;Helicobacter pylori&lt;/em&gt; Proteins with Colorectal Adenoma and Colorectal Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452767-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Helicobacter pylori (H. pylori) has been implicated in colorectal carcinogenesis. Here, the association of immune responses to bacterial exposure with advancing stages of colorectal neoplasia was assessed by multiplex serology. Immunoglobulin (Ig) A and G antibody responses to thirteen proteins of H. pylori were measured by a Luminex-based multiplex assay in plasma from patients with colorectal cancer (CRC, n = 25), advanced adenoma (n = 82), or small polyps (n = 85) and controls (n = &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452778/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Cats: The New Challenge for Rabies Control in the State of Yucatan, Mexico</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452778-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The growing population in Yucatan has led to the expansion of construction in the Mayan jungle for tourist spaces, residential areas, and agriculture. Recently, rabies cases in cats (Felis catus) have increased in the state. This study aimed to perform antigenic and genetic characterization of the rabies viruses in felines and to present the spatial distribution and environmental features of the areas where these cases were reported. The ArcGIS software and R were employed to generate &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453356/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453356-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453357/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Uric Acid and SGLT2 Inhibition With Empagliflozin in HeartÂ Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453357-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Hyperuricemia is a common complication in HFpEF and is related to advanced disease severity and adverse outcome. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Palliative neurology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453489-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Palliative medicine represents the holistic multiprofessional treatment of severely and incurably ill people and their relatives, addressing their complex physical, psychological, social and spiritual needs. The central therapeutic goals are the quality of life and alleviation of suffering. In the course of many neurological diseases, high symptom burden, long and variable trajectories and unfavorable prognosis at times create a need for palliative care even at an early stage, which is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453520/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Correction to: The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453520-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453658/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Testosterone and Quality of Life in Transgender and Gender-Diverse Adults Seeking Masculinization: A Secondary Analysis of a Randomized Clinical Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453658-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453683/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453683-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: TaqMan array card measurements were found to be biologically valid and technically reproducible. The BioPac multianalyte marker panel is capable of sensitive and accurate detection of recurrence in patients resected for PDAC using a simple blood test. This could allow a closer follow-up using shorter time intervals than currently used for imaging, thus potentially prompting an earlier work-up with additional modalities to allow for earlier therapeutic intervention. This &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453757/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453757-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453772/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453772-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453837-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453837-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OD8NCsoK0">è¿™ä¸¤å¤©åšæ–‡çŒ®ç»¼è¿°ï¼Œçœ‹åˆ°å››å¹´å†…LENåŒ–å­¦åˆæˆå‘äº†Scienceï¼Œpreclinicalå‘äº†Natureï¼Œæ²»ç–—CAPELLAå‘äº†NEJMï¼ŒPrEPå‘äº†NEJMï¼ˆè¿™äº›æˆ‘å¾®åšéƒ½å†™è¿‡ï¼Œä½†ä»æ²¡è¿èµ·æ¥è¯»è¿‡ï¼‰ã€‚å·¥...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-od8ncsok0/">
    
    
    
    
    
      
    
    è¿™ä¸¤å¤©åšæ–‡çŒ®ç»¼è¿°ï¼Œçœ‹åˆ°å››å¹´å†…LENåŒ–å­¦åˆæˆå‘äº†Scienceï¼Œpreclinicalå‘äº†Natureï¼Œæ²»ç–—CAPELLAå‘äº†NEJMï¼ŒPrEPå‘äº†NEJMï¼ˆè¿™äº›æˆ‘å¾®åšéƒ½å†™è¿‡ï¼Œä½†ä»æ²¡è¿èµ·æ¥è¯»è¿‡ï¼‰ã€‚å·¥ä¸šç•Œè¶Šæ¥è¶Šé‡è§†å‘é¡¶åˆŠï¼ŒFDAå’ŒCDCè¶Šæ¥è¶ŠæŠŠpeer reviewedé¡¶åˆŠå½“ä½œå®¡æ‰¹å’ŒæŒ‡å—æ ‡å‡†ï¼Œå› ä¸ºå®ƒä»¬éƒ½ç›¸ä¿¡é¡¶åˆŠä¿¡èª‰ï¼Œè¿™æ˜¯å‡ºç‰ˆä¸šè”“å»¶åˆ°å·¥ä¸šç•Œçš„è¡¨ç°ã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/OD8WQCe6w">#å››åˆå¦‚æ„##å“€çœ #å·¥ä½œä¸ƒå¹´åçš„ä¸€æ¬¡ç­”è¾©[æ±‚é¥¶]åˆ›ä½œä¹‹ç¥ä¸‰æ›´æˆæ³•ï¼ŒäºŒåå››å‹è€³æé¢å‘½[æ‰“call] - è½¬å‘ @å¤æ—¦åˆ›æ„å†™ä½œ:&amp;ensp;æ¬¢è¿å¤§å®¶æ¥ï¼ä¼šè®®é¢„å‘Š | å†²å‡ºæ—¥å¸¸â€”â€”å¼ ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-od8wqce6w/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted -->#å››åˆå¦‚æ„#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å“€çœ #<!-- raw HTML omitted --><!-- raw HTML omitted -->å·¥ä½œä¸ƒå¹´åçš„ä¸€æ¬¡ç­”è¾©<!-- raw HTML omitted -->&lt;img alt=&quot;[æ±‚é¥¶]&quot; src=&ldquo;<a href="https://h5.sinaimg.cn/m/emoticon/icon/default/fb_a2qiurao-7ad34b9c84.png%22">https://h5.sinaimg.cn/m/emoticon/icon/default/fb_a2qiurao-7ad34b9c84.png&quot;</a> style=&ldquo;width:1em; height:1em;&rdquo; referrerpolicy=&ldquo;no-ref &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/ODcgHjJ5W">ä»Šå¤©å°è¯´å†™ä½œå®è·µä¸¤ç»„ç´ æå±•ç¤ºéƒ½å¾ˆæ£’ï¼Œå››æ¬¡äºšå†›çš„å¥³å›´æ£‹æ‰‹ï¼Œè·¨å›½æ¶ˆå¤±çš„å°‘å¥³åŠåæ¥å‘¢[ç¬‘cry] [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-odcghjj5w/">
    
    
    
    
    
      
    
    ä»Šå¤©å°è¯´å†™ä½œå®è·µä¸¤ç»„ç´ æå±•ç¤ºéƒ½å¾ˆæ£’ï¼Œå››æ¬¡äºšå†›çš„å¥³å›´æ£‹æ‰‹ï¼Œè·¨å›½æ¶ˆå¤±çš„å°‘å¥³åŠåæ¥å‘¢<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/62b0d24fgy1huys9nf2hxj21400u0dnh.jpg%22">https://tvax4.sinaimg.cn/large/62b0d24fgy1huys9nf2hxj21400u0dnh.jpg&quot;</a> referrerpolicy=&ldquo;no-re &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/ODcp8tM21">[ç¬‘cry]è¿™å‘¨ä¹Ÿæœ‰åŒå­¦é˜…è¯»ä½œä¸šå†™é›ªæ¢¨Â·æ°å…‹é€Šçš„ã€Šç›æŸ±ã€‹ - è½¬å‘ @Evianä¸€æœµ:&amp;ensp;åˆšåˆšçœ‹å®Œæ€¡å¾®è€å¸ˆ@å¼ æ€¡å¾® åœ¨å°è¯´ç•Œå‘è¡¨çš„æ–°çŸ­ç¯‡ã€Šçœ‹è§ç›æŸ±çš„å¯»å¸¸ä¸€å¤©ã€‹ï¼Œæœ€åˆçŸ¥...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-odcp8tm21/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->è¿™å‘¨ä¹Ÿæœ‰åŒå­¦é˜…è¯»ä½œä¸šå†™é›ªæ¢¨Â·æ°å…‹é€Šçš„ã€Šç›æŸ±ã€‹<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@Evianä¸€æœµ<!-- raw HTML omitted -->:â€‚åˆšåˆšçœ‹å®Œæ€¡å¾®è€å¸ˆ<!-- raw HTML omitted -->@å¼ æ€¡å¾®<!-- raw HTML omitted --> åœ¨å°è¯´ç•Œå‘è¡¨çš„æ–°çŸ­ç¯‡ã€Šçœ‹è§ç›æŸ±çš„å¯»å¸¸ä¸€å¤©ã€‹ï¼Œæœ€åˆçŸ¥æ™“ç¯‡åæ—¶æƒ³åˆ°äº†é›ªæ¢¨Â·æ°å…‹é€Šï¼Œç›´è‡³åœ¨åè®°è¯»åˆ°è€å¸ˆå¼•ä½™å…‰ä¸­çš„è¯—å¥æ‰çŸ¥ï¼Œè¿™é‡Œè¿˜æœ‰è€å¸ˆåŒ å¿ƒç‹¬ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeCD8Wzl">ğŸ”»é»å·´å«©åª’ä½“æ´å¼•çœŸä¸»å…šå‘å¸ƒçš„æ–°è§†é¢‘ï¼šåœ¨é»å·´å«©è¾¹å¢ƒé™„è¿‘çš„æ‰é‡Œç‰¹å®šå±…ç‚¹ï¼ŒçœŸä¸»å…šæ­¦è£…ä½¿ç”¨é’»çŸ³çº¿å¯¼åå¦å…‹å¯¼å¼¹ï¼Œæ‰“æ‰ä»¥å†›ä¸€è¾†æ¢…å¡ç“¦å¦å…‹ã€‚ğŸ”»å¯ä»¥çœ‹åˆ°ï¼Œå°„å‡»è·ç¦»...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odecd8wzl/">
    
    
    
    
    
      
    
    ğŸ”»é»å·´å«©åª’ä½“æ´å¼•çœŸä¸»å…šå‘å¸ƒçš„æ–°è§†é¢‘ï¼šåœ¨é»å·´å«©è¾¹å¢ƒé™„è¿‘çš„æ‰é‡Œç‰¹å®šå±…ç‚¹ï¼ŒçœŸä¸»å…šæ­¦è£…ä½¿ç”¨é’»çŸ³çº¿å¯¼åå¦å…‹å¯¼å¼¹ï¼Œæ‰“æ‰ä»¥å†›ä¸€è¾†æ¢…å¡ç“¦å¦å…‹ã€‚<!-- raw HTML omitted -->ğŸ”»å¯ä»¥çœ‹åˆ°ï¼Œå°„å‡»è·ç¦»ç›¸å½“è¿œï¼Œå¯¼å¼¹é£è·ƒä¸€ä¸ªå±±ä¸˜åˆ°è¾¾é«˜ç‚¹ï¼Œå†æ”»é¡¶è¢­å‡»äº†ä»¥å†›å¦å…‹ã€‚<!-- raw HTML omitted -->ğŸ”»æˆ˜æ–—æ—¶é—´æ˜¯10æœˆ19æ—¥ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å·´å‹’æ–¯å¦å¥³å­©è¢«å½“ä½œäººè‚‰ç›¾ç‰Œæ¢è·¯ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeFUbkeF">ğŸ”»ä¹‹å‰æˆ‘è¯´æœé²œå¤§åŸå¸‚èƒ½ç”¨æ‰«ç ä»˜æ¬¾ï¼Œæœ‰äº›ç½‘å‹ä¸ä¿¡ã€‚ğŸ”»è¿™æ˜¯èµµä»£è¡¨åœ¨å¹³å£¤çš„äº²èº«ä½“éªŒï¼ŒçœŸçš„èƒ½æ‰«ã€‚ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odefubkef/">
    
    
    
    
    
      
    
    ğŸ”»ä¹‹å‰æˆ‘è¯´æœé²œå¤§åŸå¸‚èƒ½ç”¨æ‰«ç ä»˜æ¬¾ï¼Œæœ‰äº›ç½‘å‹ä¸ä¿¡ã€‚<!-- raw HTML omitted -->ğŸ”»è¿™æ˜¯èµµä»£è¡¨åœ¨å¹³å£¤çš„äº²èº«ä½“éªŒï¼ŒçœŸçš„èƒ½æ‰«ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeH8FW2G">ğŸ”»æ–¯æ‹‰å¤«å¤§åŒºæ—¥å¸¸ã€‚ åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeh8fw2g/">
    
    
    
    
    
      
    
    ğŸ”»æ–¯æ‹‰å¤«å¤§åŒºæ—¥å¸¸ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/1xwsXRmvlx08j4L0Od0k010412005cqG0E010.mp4?labe">https://f.video.weibocdn.com/o0/1xwsXRmvlx08j4L0Od0k010412005cqG0E010.mp4?labe</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeIRdE0h">ğŸ”»å¤§é‡ç¾å†›åŠ æ²¹æœºæ­£åœ¨é£è¡Œã€‚ğŸ”»via ads-b ex#å·´å‹’æ–¯å¦å¥³å­©è¢«å½“ä½œäººè‚‰ç›¾ç‰Œæ¢è·¯# [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeirde0h/">
    
    
    
    
    
      
    
    ğŸ”»å¤§é‡ç¾å†›åŠ æ²¹æœºæ­£åœ¨é£è¡Œã€‚<!-- raw HTML omitted -->ğŸ”»via ads-b ex<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å·´å‹’æ–¯å¦å¥³å­©è¢«å½“ä½œäººè‚‰ç›¾ç‰Œæ¢è·¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/639b1bfbly1huz32pvt1gj20u00kfn9t.jpg%22">https://tvax4.sinaimg.cn/large/639b1bfbly1huz32pvt1gj20u00kfn9t.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeMl2UXi">ğŸ”»è¿™æ˜¯è¿™äº›å¤©ç¾å›½å¤§é€‰è®¨è®ºä¸­ï¼Œç¾å›½ç½‘å‹å›å¿†çš„â€œç¾å›½æ¢¦â€ã€‚ğŸ”»å›¾1ï¼ˆ1947å¹´ï¼‰ï¼Œä¿„å…‹æ‹‰è·é©¬å·å¡”å°”è¨ï¼Œå‚åŠ æ´¾å¯¹çš„é’å°‘å¹´ã€‚ğŸ”»å›¾2ï¼ˆ1947å¹´ï¼‰ï¼Œå®¶åº­ä¸»å¦‡ä¸ä¸€å‘¨çš„æ—¥...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeml2uxi/">
    
    
    
    
    
      
    
    ğŸ”»è¿™æ˜¯è¿™äº›å¤©ç¾å›½å¤§é€‰è®¨è®ºä¸­ï¼Œç¾å›½ç½‘å‹å›å¿†çš„â€œç¾å›½æ¢¦â€ã€‚<!-- raw HTML omitted -->ğŸ”»å›¾1ï¼ˆ1947å¹´ï¼‰ï¼Œä¿„å…‹æ‹‰è·é©¬å·å¡”å°”è¨ï¼Œå‚åŠ æ´¾å¯¹çš„é’å°‘å¹´ã€‚<!-- raw HTML omitted -->ğŸ”»å›¾2ï¼ˆ1947å¹´ï¼‰ï¼Œå®¶åº­ä¸»å¦‡ä¸ä¸€å‘¨çš„æ—¥ç”¨å“åˆå½±ã€‚å¥¹æ€»å…±èŠ±äº† 12.50 ç¾å…ƒï¼ˆä¸åŒ…æ‹¬ç‰›å¥¶ï¼‰è´­ä¹°æ—¥ç”¨å“ã€‚åœ¨è¿™æ ·çš„é¢„ç®—ä¸‹ï¼Œå¥¹èƒ½å¤Ÿå…»æ´»è‡ªå·±ã€ä¸ˆå¤«ã€å››å²çš„åŒèƒèƒå’Œä»–ä»¬çš„çŒ«ã€‚<!-- raw HTML omitted -->ğŸ”»å›¾3ï¼ˆ1954å¹´ï¼‰ï¼Œä¸€ä¸ªç¦ç‰¹å·¥äººå®¶åº­ã€‚<!-- raw HTML omitted -->ğŸ”»å›¾4ï¼ˆ1959å¹´ï¼‰ï¼Œä¸€ä¸ªç¾å›½å®¶åº­ã€‚<!-- raw HTML omitted -->ğŸ”»1947å¹´çš„12.5ç¾å…ƒå·®ä¸å¤šç›¸å½“äºç°åœ¨çš„120-140ç¾å…ƒï¼Œå‚ä¸è®¨è®ºçš„æ¯ä¸ªç¾å›½äººéƒ½åœ¨éª‚ç¾å›½æ”¿åºœã€‚<!-- raw HTML omitted -->ğŸ”»ç¾å›½ä¸ºä»€ä¹ˆä¼šè¿™æ ·ï¼Ÿç¬¬äºŒæ¬¡å†²å‡»å¡è„–å­äº†ï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ç¾å›½å¤§é€‰#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containe">https://m.weibo.cn/search?containe</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeQnc0fI">ğŸ”»â€¦â€¦å“¦å¤©å•Šã€‚ åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeqnc0fi/">
    
    
    
    
    
      
    
    ğŸ”»â€¦â€¦å“¦å¤©å•Šã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/nLdGm0DNlx08j4MzBoxq01041200bZ8o0E010.mp4?label=m">https://f.video.weibocdn.com/o0/nLdGm0DNlx08j4MzBoxq01041200bZ8o0E010.mp4?label=m</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODf7knA9l">ğŸ”»æœ€æ–°æ¶ˆæ¯ - åé‚®å®£å¸ƒï¼šâ€œä¸ä¼šä¸ºä»»ä½•æ€»ç»Ÿå€™é€‰äººèƒŒä¹¦ã€‚â€ğŸ”»ç³Šæ¶‚å•Šï¼Œå¿ è¯šä¸ç»å¯¹ï¼Œå°±æ˜¯ç»å¯¹ä¸å¿ è¯šã€‚#ç¾å›½å¤§é€‰# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odf7kna9l/">
    
    
    
    
    
      
    
    ğŸ”»æœ€æ–°æ¶ˆæ¯ - åé‚®å®£å¸ƒï¼šâ€œä¸ä¼šä¸ºä»»ä½•æ€»ç»Ÿå€™é€‰äººèƒŒä¹¦ã€‚â€<!-- raw HTML omitted -->ğŸ”»ç³Šæ¶‚å•Šï¼Œå¿ è¯šä¸ç»å¯¹ï¼Œå°±æ˜¯ç»å¯¹ä¸å¿ è¯šã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ç¾å›½å¤§é€‰#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODffgyf0i">ğŸ”»é»å·´å«©ç›‘æ§è§†é¢‘ï¼šä»¥å†›ç©ºè¢­æå°”åŸï¼Œå‘½ä¸­äº†æ‹‰å¸Œè¿ªè€¶è¥åœ°çš„æµ·æ»©ï¼Œä»€ä¹ˆéƒ½æ²¡æ‰“ä¸­ã€‚ğŸ”»æ‰€ä»¥æœ‰æ—¶å€™è¿œè·ç¦»çœ‹åˆ°ç±»ä¼¼è¿™æ ·çš„ç«å…‰è§†é¢‘ï¼Œå¹¶ä¸ä»£è¡¨å°±æ‰“ä¸­äº†ä»€ä¹ˆâ€œå¼¹è¯åº“â€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odffgyf0i/">
    
    
    
    
    
      
    
    ğŸ”»é»å·´å«©ç›‘æ§è§†é¢‘ï¼šä»¥å†›ç©ºè¢­æå°”åŸï¼Œå‘½ä¸­äº†æ‹‰å¸Œè¿ªè€¶è¥åœ°çš„æµ·æ»©ï¼Œä»€ä¹ˆéƒ½æ²¡æ‰“ä¸­ã€‚<!-- raw HTML omitted -->ğŸ”»æ‰€ä»¥æœ‰æ—¶å€™è¿œè·ç¦»çœ‹åˆ°ç±»ä¼¼è¿™æ ·çš„ç«å…‰è§†é¢‘ï¼Œå¹¶ä¸ä»£è¡¨å°±æ‰“ä¸­äº†ä»€ä¹ˆâ€œå¼¹è¯åº“â€ï¼Œä¹Ÿå¯èƒ½æ˜¯ä»¥å†›å¼¹è¯è‡ªå¸¦çš„æ•ˆæœï¼Œä»¥å†›çš„å®£ä¼ è€è¿™ä¹ˆè¯´ï¼Œæ»¡åœ°éƒ½æ˜¯å®ƒä»¬æ‰“ä¸­çš„â€œå¼¹è¯åº“â€ã€‚<!-- raw HTML omitted -->ğŸ”»via al-mayadeen ç”µè§†å°<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODfXpxWST">ğŸ”»å—æ½­ç¾å½±å“ï¼Œè²å¾‹å®¾å…«æ‰“é›çœå·²æœ‰ 47 äººæ­» äº¡ã€‚æ®è²å¾‹å®¾ç¤¾ä¼šç¦åˆ©ä¸å‘å±•éƒ¨ç§°ï¼Œè²å¾‹å®¾å·²æœ‰è¶…è¿‡ 330 ä¸‡äººå—ç¾ï¼Œå…¶ä¸­æœ‰ 28.8 ä¸‡äººï¼ˆåŒ…æ‹¬ 7.5 ä¸‡ä¸ªå®¶åº­ï¼‰ä»ä½åœ¨ 33...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odfxpxwst/">
    
    
    
    
    
      
    
    ğŸ”»å—æ½­ç¾å½±å“ï¼Œè²å¾‹å®¾å…«æ‰“é›çœå·²æœ‰ 47 äººæ­» äº¡ã€‚æ®è²å¾‹å®¾ç¤¾ä¼šç¦åˆ©ä¸å‘å±•éƒ¨ç§°ï¼Œè²å¾‹å®¾å·²æœ‰è¶…è¿‡ 330 ä¸‡äººå—ç¾ï¼Œå…¶ä¸­æœ‰ 28.8 ä¸‡äººï¼ˆåŒ…æ‹¬ 7.5 ä¸‡ä¸ªå®¶åº­ï¼‰ä»ä½åœ¨ 3300 ä¸ªæ”¿åºœåº‡æŠ¤æ‰€ä¸­ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å°é£æ½­ç¾è¿›å…¥24å°æ—¶è­¦æˆ’çº¿#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODg116xmT">è¢«é»å·´å«©æŠµæŠ—ç»„ç»‡æ‰“æ­»çš„ï¼Œå°±æ˜¯è¿™ä¸ªæ¡ˆä»¶çš„å‡¶ æ‰‹ã€‚ æŸ¥çœ‹å›¾ç‰‡ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»çº¦æ—¦è¥¿å²¸éæ³•å®šå±…ç‚¹æœ€å±é™©ã€æœ€æš´åŠ›çš„éæ³•å®šå±…è€…ä¹‹ä¸€èˆ’ç“¦è‰¾å°”-æœ¬-çº³...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odg116xmt/">
    
    
    
    
    
      
    
    è¢«é»å·´å«©æŠµæŠ—ç»„ç»‡æ‰“æ­»çš„ï¼Œå°±æ˜¯è¿™ä¸ªæ¡ˆä»¶çš„å‡¶ æ‰‹ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¥çœ‹å›¾ç‰‡<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»çº¦æ—¦è¥¿å²¸éæ³•å®šå±…ç‚¹æœ€å±é™©ã€æœ€æš´åŠ›çš„éæ³•å®šå±…è€…ä¹‹ä¸€èˆ’ç“¦è‰¾å°”-æœ¬-çº³å¦ï¼ˆShoval Ben Natanï¼‰ä½œä¸ºåº”å¾å…¥ä¼çš„ä»¥å†›ï¼Œåˆšåˆšåœ¨é»å·´å«©å—éƒ¨è¢«æ‰“æ­»ã€‚<!-- raw HTML omitted -->ğŸ”»ä»–æ˜¯æœ¬ &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

